Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease

Summary

This early phase I trial tests the safety, side effects and how well medication combinations of dasatinib, quercetin, fisetin and temozolomide work in treating patients with glioma for which the patient has received treatment in the past (previously treated) and for tumor cells that remain after attempts to treat the tumor have been made (residual disease). Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply, which may help keep tumor cells from growing. Quercetin and fisetin are compounds found in plants. They have antioxidant and anti-inflammatory properties and help remove senescent cells, older or damaged cells that have stopped dividing but don't die off as they should and build up in tissues over time. Senescent cells may cause inflammation or damage to nearby healthy cells. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells and slow down or stop tumor growth. Giving medication combinations of dasatinib, quercetin, fisetin and temozolomide may be safe, tolerable and/or effective in treating patients with previously treated glioma with residual disease.

Conditions

• Glioma

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood and CSF sample collection

DRUG

Dasatinib

Given PO

DRUG

Fisetin

Given PO

DRUG

Fluorodopa F 18

Undergo 18F-DOPA-PET scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

OTHER

Patient Observation

Receive rest and take no treatment

PROCEDURE

Positron Emission Tomography

Undergo 18F-DOPA-PET scan

DRUG

Quercetin

Given PO

DRUG

Temozolomide

Given PO

Sponsors & Collaborators

• Mayo Clinic

  lead OTHER

Principal Investigators

• Terence C. Burns, MD, PhD · Mayo Clinic in Rochester

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-08-12

Primary Completion

2027-09-01

Completion

2027-09-01

FDA Drug

Yes

Countries

• United States

Study Locations